Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric MATCH Subprotocol I: Palbociclib in Cell Cycle Gene Altered Tumors
NCT03526250Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in solid tumor, non-Hodgkin lymphoma (NHL) and histiocytic disorder, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 2 years. Started Aug 2018; status: completed.
02
Drugs
palbociclib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)histiocytic disorder
Beyond the preview
Go deeper on NCT03526250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526250.